Abstract #1795: In Vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2.
Year: 2009
Type: conference-abstract
Source: Cancer Research
Authors: Tracy Pheneger, Karyn Bouhana, Deborah Anderson, Jennifer Garrus, Kateri A. Ahrendt, Shelley J Allen, Ira von Carlowitz, Julie Greschuk, Stefan Groß, Keith L. Hoffman, Christine Lemieux, Joe Lyssikatos, Michele Callejo, Gene Tarlton, Eli Wallace, Shannon L. Winski, Rich Woessner, Qian Zhao, Fred P. Marmsater, Patrice Lee
Institution: Array BioPharma (United States)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: HER2, small-molecule kinase inhibitors, ErbB receptors, breast cancer, ovarian cancer, gastric cancer, tumor xenografts, Akt phosphorylation, apoptosis, ADME properties, oral bioavailability, drug metabolism, trastuzumab, lapatinib, targeted cancer therapy, tumor growth inhibition, BT474 cells, NCI-N87 cells, dose-limiting toxicity
Open Access status: closed
OpenAlex ID: W3163885867
